iBio Inc
Company Profile
Business description
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Contact
11750 Sorrento Valley Road
Suite 200
San DiegoCA92121
USAT: +1 979 446-0027
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
23
iBio Inc News & Analysis
stocks
Looking under the hood at Robinhood
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,711.10 | 125.50 | -1.42% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 57,097.59 | 2,346.62 | -3.95% |
| NZX 50 Index | 14,164.76 | 82.49 | -0.58% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,609.90 | 120.50 | -1.38% |
| SSE Composite Index | 3,577.08 | 0.54 | -0.02% |